

NCTN—View from a Lead Academic Site/Cancer Center

Nancy E. Davidson, MD

Hillman Professor of Oncology

Director, University of Pittsburgh Cancer Institute and UPMC CancerCenter





University of Pittsburgh Cancer Institute (UPCI)


























- 320 faculty members from 42 academic departments at University of Pittsburgh
- Clinical research and care through UPMC hospitals and cancer centers


Thriving UPMC CancerCenter Network



Stanley Marks, MD



Peter Ellis, MD



Dwight Heron, MD




Charles Bogosta












Accrual to Interventional Clinical Trials at UPCI UPMC CancerCenter (2004 – 2013)



■ Institutional
■ External Peer Review
■ National Group
□ Industry

National Clinical Trials Network (NCTN)



Costantino

- Group Statistician, NRG
- NRG Biostatistical Office headquartered at University of Pittsburgh



Brufsky





Chu

Early
Therapeutics
Clinical Trials
Network Site
(UM1CA099168)

Cooperative Groups Consolidation



National Surgical Adjuvant Breast and Bowel Project













Cooperative Groups Consolidation











UPCI Participated in 8 Cooperative Groups

Cooperative Groups Consolidation











UPCI Participating in 4 Cooperative Groups

Potential Advantages for LAPS

- Single grant—streamlined finances and administration
- Use of NCI CIRB
- Enhanced case reimbursement
- Provided internal mandate to assemble a steering committee led by UPCI AD for Clinical Investigation to oversee NCTN accruals and allocate resources—better integration

Potential Disadvantages for LAPS

- Shifting focus and loyalty from legacy to new cooperative groups
- Maintaining engagement of LAPS leaders with scientific leadership of new cooperative groups
- Encouraging NCTN involvement for young investigators given lack of opportunity to "lead"
- Financial penalty for "overaccrual"

What We Must Consider.....

- Impact of a more centrally directed NCTN in the field
- How a goal of smaller biologically based trials will be implemented in the community
- Interactions between and roles of the component parts to advance the clinical trials agenda—cooperative groups, LAPS, NCORPs, ET-CTN, SPOREs, CCSGs, etc